Surface Oncology operates two wholly-owned clinical-stage programs targeting IL-27 (SRF388) and CCR8 (SRF114), plus partnerships with Novartis targeting CD73 and GlaxoSmithKline targeting PVRIG. As a pre-revenue clinical-stage company, execution in clinical trials and regulatory progression represent the primary value drivers and execution risks.
Cyborg Score Rationale
Surface Oncology trades at a $65M market cap with significantly depressed valuation and no approved products or meaningful revenue. Stock performance lags both biotech peers and broad market, suggesting limited institutional confidence in pipeline progression and capital deployment efficiency.
Top Insights
Market cap of $65.08M with 60.82M shares outstanding. Stock trading near 52-week low signals limited investor confidence in pipeline advancement and capital runway sustainability.
Company developing multiple antibody candidates targeting innate and adaptive immunity barriers, with lead programs SRF388 (IL-27) and SRF114 (CCR8). Pipeline breadth requires significant capital; limited market cap suggests funding constraints.
Stock underperformed US Biotech and broad market returns over past year. Underperformance reflects clinical progress uncertainty and potential execution or partnering setbacks relative to peer expectations.
Named Competitors
Keytruda — Anti-PD-1 checkpoint inhibitor for immuno-oncology
Opdivo — Anti-PD-1 checkpoint inhibitor and combination therapies